A brief review and case report of pheochromocytoma misdiagnosed as allergic vasculitis with bilateral lower extremity ulcers: a 24-year clinical course.
We report a 36-year-old male with pheochromocytoma presenting solely as progressive bilateral lower limb necrosis for 24 years, lacking classic symptoms (hypertension, headache, palpitations).
APA
Li R, Cao Z, et al. (2026). A brief review and case report of pheochromocytoma misdiagnosed as allergic vasculitis with bilateral lower extremity ulcers: a 24-year clinical course.. Frontiers in endocrinology, 17, 1773861. https://doi.org/10.3389/fendo.2026.1773861
MLA
Li R, et al.. "A brief review and case report of pheochromocytoma misdiagnosed as allergic vasculitis with bilateral lower extremity ulcers: a 24-year clinical course.." Frontiers in endocrinology, vol. 17, 2026, pp. 1773861.
PMID
42039137
Abstract
We report a 36-year-old male with pheochromocytoma presenting solely as progressive bilateral lower limb necrosis for 24 years, lacking classic symptoms (hypertension, headache, palpitations). Misdiagnosed as allergic vasculitis, he developed atrophic scars and toe necrosis despite immunosuppression. Elevated catecholamines and a 4.8 cm adrenal mass confirmed the diagnosis. Postoperatively, ulcers healed, but toe amputation was needed. This case highlights diagnostic pitfalls of atypical pheochromocytoma, emphasizing dynamic biomarker monitoring for early detection.
MeSH Terms
Humans; Pheochromocytoma; Male; Adult; Adrenal Gland Neoplasms; Diagnostic Errors; Vasculitis; Lower Extremity; Hypersensitivity
같은 제1저자의 인용 많은 논문 (5)
- From numerical amplification to functional metamorphosis: the MDSC-driven therapeutic resistance in tumor.
- Symptom Clusters in Children With Leukemia Receiving Chemotherapy: A Scoping Review.
- Ginkgetin inhibits non-small cell lung cancer via the HSP90-AKT signaling pathway.
- Global trends and inequities in childhood cancer burden from 1990 to 2021, with projections to 2040: a Global Burden of Disease study.
- Design, synthesis and biological evaluation of novel glutaminyl cyclase inhibitors targeting the CD47-SIRPα axis in breast cancer cells.